Figure 8 Antitumor effect of various nanoparticles in comparison with that of PBS. Figure 9 Representative H&E staining of tumors. Treated with PBS (A), TRAIL-loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles (B), endostatin-loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles (C), and TRAIL and endostatin-loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles (D). In future studies, we will investigate the combined effect of TRAIL/endostatin gene therapy and chemotherapeutic agents such as doxorubicin, docetaxel, and floxuridine, encapsulated
in TPGS-b-(PCL-ran-PGA) nanoparticles, in different cervical cancer cell lines and animal models in order to make clear whether a combination of TRAIL/endostatin gene therapy and chemotherapy will have enhanced antitumor activity. We hypothesize that surface modification of TPGS-b-(PCL-ran-PGA) MAPK inhibitor nanoparticles with polyethyleneimine may also be a promising and useful drug and gene co-delivery system. Raf inhibitor Conclusions For the first time, a novel TPGS-b-(PCL-ran-PGA) nanoparticle
modified with polyethyleneimine was applied to be a vector of TRAIL and endostatin for cervical cancer gene therapy. The data showed that the nanoparticles could efficiently deliver plasmids into HeLa cells and the expression of TRAIL and endostatin was verified by RT-PCR and Western blot analysis. The cytotoxicity of the HeLa cells was significantly increased by TRAIL/endostatin-loaded nanoparticles when compared with control groups. Synergistic antitumor activities could be obtained by the use of combinations of TRAIL, endostatin, and TPGS. The images of H&E staining also indicated that tumor growth treated by TRAIL- and endostatin-loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles was significantly inhibited in comparison with that of the PBS control. In conclusion, the TRAIL/endostatin-loaded nanoparticles offer considerable potential as an ideal candidate for in vivo cancer gene
delivery. Acknowledgements The authors gratefully acknowledge the financial support from the Natural Science Foundation of Guangdong Province (S2012010010046), Science, Technology and Innovation Commission of Shenzhen Municipality (JC200903180532A, JC200903180531A, mTOR inhibitor JC201005270308A, KQC201105310021A, and JCYJ20120614191936420), Doctoral Fund of Ministry of Education of China (20090002120055), Nanshan District Bureau of Science and Technology, National Natural Science Foundation of China (31270019, 51203085), and Program for New Century Excellent Talents in University (NCET-11-0275). References 1. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153–156.CrossRef 2. Ma Y, Huang L, Song C, Zeng X, Liu G, Mei L: Nanoparticle formulation of poly(ε-caprolactone-co-lactide)-d-α-tocopheryl polyethylene glycol 1000 succinate random copolymer for cervical cancer treatment. Polymer 2010, 51:5952–5959.CrossRef 3.